| ARVO Home | Mobile Version | Print-Friendly Version | Send to a Friend |
August 25, 2017


What's coming? A new look for arvo.org
Get ready for ARVO's new, desktop- and mobile-friendly website. Stay tuned; We'll be going live this fall.



 

American Academy of Ophthalmology
Nov. 11 - 14
New Orleans, La.
Booth 3513 

Society for Neuroscience 
Nov. 11 - 15
Washington, D.C.
Booth 3316


Manage ARVO e-News
Search Back Issues

In This Issue
ARVO responds to NIH proposed definition of clinical trials
Events & education
Did you miss a session?
Foundation news
Final call: Complete your applications, nominations
U.S. Advocacy
ARVO opposes cuts to NIH grants
International Chapter Affiliates
More than 150 attended ARVO-India ICA meeting
ARVOJobs
Openings in Hong Kong and U.S. cities
Grants and awards
Funding opportunities
Awards
ARVO responds to NIH proposed definition of clinical trials

ARVO leadership recently responded to the National Institutes of Health’s redefinition of clinical trials in a letter expressing concern regarding the potential for broad interpretation of the new definition and its resulting impacts on eye and vision scientists. The letter, drafted by the ARVO Ethics and Regulations in Human Research (ERHR) Committee, was posted on the ARVOConnect Open Forum by ARVO President Claude F. Burgoyne, MD, FARVO.

The letter stated, “Many member scientists conduct basic research, using humans as experimental observers. These studies are not 'clinical trials' in the conventional usage and common understanding of the term; but the new NIH definition could put that label on a substantial body of work in our field.”

The ARVO leadership echoed “concerns expressed by others that classifying basic human research as clinical trials can confuse the public about the nature of trials and that the additional studies categorized as trials will place additional and undue burden on NIH oversight, on researchers and their institutions ….”   In addition, the leadership shared it concerns “that the grant review process will be significantly disrupted by the requirement that beginning with the January 25, 2018 grant due dates, all applications proposing clinical trials must be submitted through a FOA designated specifically for clinical trials."

Visit ARVOConnect to read the letter in its entirety and to participate in the members-only discussion on the topic.



top of page up arrow Back to Contents Page | Next Article
Association for Research in Vision and Ophthalmology
1801 Rockville Pike, Suite 400 | Rockville MD 20852-5622
tel: +1.240.221.2900 | fax: +1.240.221.0370 | arvo@arvo.org | www.arvo.org
You are receiving ARVO Insight as a member service or because of your involvement with ARVO.

View ARVO's Privacy Policy.

To ensure delivery of Insight, please add arvo@arvo.org to your e-mail address book or Safe Sender List.
If you are still having problems receiving our communications, get more information about white-listing.